ENERGÍA SOLAR TÉRMICA DE CONCENTRACIÓN

VolverVolver

Resultados 87 resultados LastUpdate Última actualización 03/10/2022 [08:48:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days



Página1 de 4 nextPage   por página


OPTICAL BASED GLUCOSE SENSOR

NºPublicación: US2022248986A1 11/08/2022

Solicitante:

MEDTRONIC INC [US]

WO_2022173643_A1

Resumen de: US2022248986A1

An example medical device includes an optical sensor, processing circuitry, an antenna, and a power source. The optical sensor includes a light source; a reference optical beacon having a first fluorophore that emits a first fluorescence proportional to a first concentration of a substance proximate the beacon; a test optical beacon having a reagent substrate that reacts with an analyte to produce the substance and a second fluorophore that emits a second fluorescence proportional to a second concentration of the substance proximate the test beacon; and a photodetector to detect the first and second fluorescence. The processing circuitry determines a difference between the first and second fluorescence, which is indicative of the concentration of the analyte. The antenna and power source enable the medical device to operate completely within a biological system for continuous analyte monitoring.

traducir

USER-WORN DEVICE FOR NONINVASIVELY MEASURING A PHYSIOLOGICAL PARAMETER OF A USER

NºPublicación: US2022248984A1 11/08/2022

Solicitante:

MASIMO CORP [US]

US_2020196882_A1

Resumen de: US2022248984A1

The present disclosure relates to noninvasive methods, devices, and systems for measuring various blood constituents or analytes, such as glucose. In an embodiment, a light source comprises LEDs and super-luminescent LEDs. The light source emits light at at least wavelengths of about 1610 nm, about 1640 nm, and about 1665 nm. In an embodiment, the detector comprises a plurality of photodetectors arranged in a special geometry comprising one of a substantially linear substantially equal spaced geometry, a substantially linear substantially non-equal spaced geometry, and a substantially grid geometry.

traducir

SYSTEMS AND METHODS FOR DETECTION AND GRADING OF DIABETIC RETINOPATHY

NºPublicación: US2022254500A1 11/08/2022

Solicitante:

UNIV LOUISVILLE RES FOUND INC [US]

WO_2021046418_A1

Resumen de: US2022254500A1

Computer-implemented systems and methods for automated diagnosis of diabetic retinopathy apply machine learning techniques to clinical and demographic data combined with optical coherence tomography and optical coherence tomography angiography image data to diagnose and grade diabetic retinopathy.

traducir

SELF-CALIBRATING GLUCOSE MONITOR

NºPublicación: WO2022169721A1 11/08/2022

Solicitante:

MEDTRONIC INC [US]

US_2022248965_A1

Resumen de: WO2022169721A1

A medical system including processing circuitry configured to receive a cardiac signal indicative of a cardiac characteristic of a patient from sensing circuitry and configured to receive a glucose signal indicative of a glucose level of the patient. The processing circuitry is configured to formulate a training data set including one or more training input vectors using the cardiac signal and one or more training output vectors using the glucose signal. The processing circuitry is configured to train a machine learning algorithm using the formulated training data set. The processing circuitry is configured to receive a current cardiac signal from the patient and determine a representative glucose level using the current cardiac signal and the trained machine learning algorithm.

traducir

TECHNIQUES AND DEVICES FOR ADAPTATION OF MAXIMUM DRUG DELIVERY LIMITS

NºPublicación: US2022249773A1 11/08/2022

Solicitante:

INSULET CORP [US]

EP_4039293_PA

Resumen de: US2022249773A1

Disclosed are techniques, a system and devices that enable the setting of an upper boundary constraint that may be a multiple of a total daily dosage setting for a liquid drug being administered to a user to control a condition, such as type 1 or type 2 diabetes mellitus. An automatic drug delivery algorithm may be configured to obtain a glucose control metric. A controller executing the automatic drug delivery algorithm may ascertain, based on the glucose control metric, an upper boundary constraint for the liquid drug that limits an amount of a dose of the liquid drug that may be delivered by the automatic drug delivery system or components thereof.

traducir

METHOD FOR TREATMENT OF NEUROCOGNITIVE DECLINE

NºPublicación: US2022249767A1 11/08/2022

Solicitante:

INVICTUS HEALTH INC [US]

US_2021322669_A1

Resumen de: US2022249767A1

A method for treating a patient with a neurodegenerative disease including performing Ketamine Infusion Therapy on the patient, performing hyperbaric oxygen therapy on the patient, intranasally infusing plasma into the patient, and intranasally infusing diluted insulin into the patient. Performing hyperbaric oxygen therapy on the patient may include placing the patient into a hyperbaric chamber, sealing and pressurizing the hyperbaric chamber, and pumping oxygen into the hyperbaric chamber while it is pressurized. Before intranasally infusing plasma into the patient, the method may include drawing blood from the patient and centrifugally extracting the plasma from the drawn blood, such as platelet rich plasma (PRP). Before drawing blood from the patient, the method may include intravenously injecting the patient with supplements, such as a combination of magnesium, calcium, B-vitamins, Vitamin C, nicotinamide adenine dinucleotide (NAD+), and Glutathione.

traducir

SYSTEMS, DEVICES, AND METHODS RELATING TO MEDICATION DOSE GUIDANCE

NºPublicación: US2022249779A1 11/08/2022

Solicitante:

ABBOTT DIABETES CARE INC [US]

Resumen de: US2022249779A1

Systems, devices and methods are provided for determining a medication dose for a patient or user. The dose determination can account for recent and/or historical analyte levels of the patient or user. The dose determination can also take into account other information about the patient or user, such as physiological information, dietary information, activity, and/or behavior. Many different dose determination embodiments are set forth, pertaining to a wide array of different aspects of the system or environment in which the embodiments can be implemented. Systems, devices and methods are provided for displaying information related to glucose levels, including a time in range display and a graph of analyte levels containing an identification of a pattern type of a segment of the day.

traducir

ITERATIVE LEARNING CONTROL WITH SPARSE MEASUREMENTS FOR INSULIN INJECTIONS IN PEOPLE WITH TYPE 1 DIABETES

NºPublicación: US2022254472A1 11/08/2022

Solicitante:

HARVARD COLLEGE [US]

WO_2021007391_A1

Resumen de: US2022254472A1

The technology described herein relates to control models for artificial pancreas systems, including insulin injections in people with diabetes. The methods provided herein allow for a modular and personalized intervention for the treatment of diabetes using an iterative learning controller (ILC). The ILC allows for long-acting insulin doses to be computationally applied to track a basal glucose concentration reference, a run-to-run (R2R) control policy to update the treatment plan, that progressively meets the recommended glycemic targets.

traducir

SYSTEM AND METHOD FOR CALCULATING RISK OF DIABETES INCIDENCE, AND PROGRAM

NºPublicación: WO2022169149A1 11/08/2022

Solicitante:

CATHOLIC UNIV KOREA IND ACADEMIC COOPERATION FOUNDATION [KR]
UNIV AJOU IND ACADEMIC COOP FOUND [KR]

KR_20220112616_PA

Resumen de: WO2022169149A1

The present invention relates to a system for calculating the risk of diabetes incidence, the system comprising: an analysis server which includes one or more computers, calculates the severity of metabolic syndrome on the basis of input metabolic syndrome incidence factor values for metabolic syndrome incidence factors, and calculates the risk of diabetes incidence from the calculated severity of metabolic syndrome, on the basis of a statistical technique; and a client connected to the analysis server, wherein the client receives, as inputs, the input metabolic syndrome incidence factor values, provides the same to the analysis server, receives the risk of diabetes incidence from the analysis server, and outputs the same, and the metabolic syndrome incidence factors may include fasting blood sugar, systolic blood pressure, waist girth, high-density lipoprotein, and triglycerides.

traducir

DIGITAL AND USER INTERFACES FOR ANALYTE MONITORING SYSTEMS

NºPublicación: US2022248988A1 11/08/2022

Solicitante:

ABBOTT DIABETES CARE INC [US]

WO_2022061144_A1

Resumen de: US2022248988A1

Improved digital interfaces, graphical user interfaces, and alarms for analyte monitoring systems are provided. For example, disclosed herein are various embodiments of methods, systems, and interfaces for signal loss condition determination, Time-in-Ranges interfaces, GMI metrics, urgent low glucose alarms, alarm suppression features, alarm setup interfaces, and alarm unavailability detection features. In addition, various embodiments of interfaces for alarm logging and compatibility checking of an analyte monitoring software application are described. Also, various embodiments of interface enhancements are described, including an enhanced visibility mode, a voice accessibility mode, additional interfaces relating to user privacy, as well as caregiver alarms, among other embodiments.

traducir

Insulin Management

NºPublicación: US2022248989A1 11/08/2022

Solicitante:

ASEKO INC [US]

EP_3926638_PA

Resumen de: US2022248989A1

A method of managing insulin includes receiving blood glucose measurements on a computing device from a glucometer. The blood glucose measurements are separated by a time interval. The method includes determining, by the computing device, an insulin dose rate based on the blood glucose measurements and determining a blood glucose drop rate based on the blood glucose measurements and the time interval. The method also includes determining a blood glucose percentage drop based on the blood glucose measurements. The method includes decreasing the time interval between blood glucose measurements by the glucometer when the blood glucose drop rate is greater than a threshold drop rate, and decreasing the time interval between blood glucose measurements by the glucometer when the blood glucose percentage drop is greater than a threshold percentage drop.

traducir

SELF-CALIBRATING GLUCOSE MONITOR

NºPublicación: US2022248965A1 11/08/2022

Solicitante:

MEDTRONIC INC [US]

WO_2022169721_A1

Resumen de: US2022248965A1

A medical system including processing circuitry configured to receive a cardiac signal indicative of a cardiac characteristic of a patient from sensing circuitry and configured to receive a glucose signal indicative of a glucose level of the patient. The processing circuitry is configured to formulate a training data set including one or more training input vectors using the cardiac signal and one or more training output vectors using the glucose signal. The processing circuitry is configured to train a machine learning algorithm using the formulated training data set. The processing circuitry is configured to receive a current cardiac signal from the patient and determine a representative glucose level using the current cardiac signal and the trained machine learning algorithm.

traducir

GLUCOSE DETECTING COMPLEX AND CONTACT LENS-TYPE SENSOR COMPRISING SAME FOR DETECTING GLUCOSE IN TEARS

NºPublicación: US2022248990A1 11/08/2022

Solicitante:

UNIV HANYANG IND UNIV COOP FOUND [KR]

Resumen de: US2022248990A1

The present invention relates to a glucose detecting complex and a contact lens-type sensor comprising the same for detecting glucose in tears. The contact lens-type sensor for detecting glucose according to the present invention includes a complex in which glucose oxidase is coupled to cerium oxide nanoparticles. Such a configuration allows the visualization of changes in glucose concentrations and the quantitative measured of glucose in a simpler and more economical way. In addition, glucose concentrations can be monitored in real time through a non-invasive method by measuring the concentration of glucose in tears rather than in blood in comparison with the conventional blood glucose measurement method. Therefore, the present invention can be widely applied in the technical field for the early diagnosis and prevention of diabetes.

traducir

Development of Imaging and Therapeutic Glucose Analogues for Sodium Dependent Glucose Transporters

NºPublicación: EP4037691A1 10/08/2022

Solicitante:

US GOV VETERANS AFFAIRS [US]
UNIV CASE WESTERN RESERVE [US]

WO_2021067738_A1

Resumen de: US2021101905A1

The present disclosure describes glucose analogs that are transported on the sodium dependent glucose transporters (SGLTs). These compounds may be useful in a variety of disorders such as, for example, cancer, heart disease, neurological disorders, diabetes, and atherosclerosis. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

traducir

USER INTERFACE FOR DIABETES MANAGEMENT SYSTEMS AND DEVICES

NºPublicación: EP4040443A1 10/08/2022

Solicitante:

BIGFOOT BIOMEDICAL INC [US]

WO_2019118541_PA

Resumen de: EP4040443A1

One or more embodiments of the disclosure relate, generally, to a diabetes management system. The diabetes management system may include a computing device that is configured to receive data relating to prior insulin use of a user and calculate a sliding scale glucose correction based, at least in part, on the data relating to prior insulin use.

traducir

SYSTEMS AND METHODS FOR AUTOMATED INSULIN DELIVERY FOR DIABETES THERAPY

NºPublicación: WO2022165518A1 04/08/2022

Solicitante:

TANDEM DIABETES CARE INC [US]

US_2022233773_A1

Resumen de: WO2022165518A1

Disclosed herein are systems and methods for automated insulin delivery that reduce a risk of hypoglycemia from automatically delivering correction boluses. Rather than automatically delivering a correction bolus when a current or future predicted glucose level of a user is over a high glucose threshold, the system can review additional factors to determine whether an automatic correction bolus is appropriate. For example, the system can be prevented from delivering an automatic correction bolus if the user's glucose levels are falling at greater than a predetermined rate and/or if a current glucose level is greater than a future predicted glucose level even if the user's current or predicted future glucose levels is over the high threshold.

traducir

SYSTEMS AND METHODS FOR INCORPORATING CO-FORMULATIONS OF INSULIN IN AN AUTOMATIC INSULIN DELIVERY SYSTEM

NºPublicación: WO2022164737A1 04/08/2022

Solicitante:

INSULET CORP [US]

US_2022241504_A1

Resumen de: WO2022164737A1

Disclosed herein are systems and methods for the delivery of a co-formulation of insulin and a second drug, such as GLP-1, using an automated insulin delivery system. In a first embodiment, a dose of insulin is calculated by a medication delivery algorithm and a reduction factor is applied to account for the effect of second drug on the user's daily insulin requirement. In a second embodiment of the invention, a total amount of the second drug administered to the user during the past 24 hours is used to modify the correction factor and the insulin-to-carbohydrate ratio used by the medication delivery algorithm to cause a reduction in the insulin delivered to the user to account for the effect of the administration of the second drug portion of the co-formulation.

traducir

PREDICTION OF BLOOD PERFUSION DIFFICULTIES BASED ON BIOMARKER MONITORING

NºPublicación: US2022241028A1 04/08/2022

Solicitante:

ETHICON LLC [US]

WO_2022157694_A1

Resumen de: US2022241028A1

Blood perfusion difficulty complication(s) may be predicted based on biomarker measurements obtained before a surgery and/or during the surgery via one or more sensing systems. For example, a computing system may monitor the patient biomarker(s) including core body temperature, peripheral temperature, blood sugar level, hydration state data, and/or oxygen saturation data. Based on the prediction, the computing system may generate a control signal configured to alter a matter in which a surgical cutting and stapling device and/or a surgical energy operate, to adjust a surgical procedure plan, to adjust a surgical instrument selection, indicate a probability of the blood perfusion difficulty complication, and/or to indicate a suggested adjustment to surgical procedure plan, surgical approach, and/or surgical instrument selection.

traducir

INSULIN STORAGE AND DISPENSING SYSTEM

NºPublicación: US2022241150A1 04/08/2022

Solicitante:

COLGAN JACK WAYNE [US]

Resumen de: US2022241150A1

An insulin storage and dispensing system for housing a standard insulin bottle and securely keeping the bottle in place when using a syringe to access the port on the top of the bottle to fill the syringe while providing accessibility in the form of a convenient mounting assembly for mounting on a refrigerator, an interior cabinet door or wall.

traducir

Systems and Methods for Risk Based Insulin Delivery Conversion

NºPublicación: US2022246265A1 04/08/2022

Solicitante:

DEXCOM INC [US]

US_2022256227_A1

Resumen de: US2022246265A1

Systems and methods are provided for managing hyperglycemia and hypoglycemia by reconciling incoming data to provide safe and reliable control to range using automatic bolus determination wherein the rate of insulin delivery is dependent on the level of hyperglycemic risk or hypoglycemic risk. Additionally, some implementations are directed to converting insulin delivery into a rate based on glycemic risk.

traducir

BLOOD SUGAR MANAGEMENT DEVICE, BLOOD SUGAR MANAGEMENT SYSTEM, BLOOD SUGAR MANAGEMENT METHOD, AND BLOOD SUGAR MANAGEMENT PROGRAM

NºPublicación: US2022246278A1 04/08/2022

Solicitante:

TERUMO CORP [JP]

CN_114599269_PA

Resumen de: US2022246278A1

A blood sugar management device includes a blood sugar information acquisition unit, a meal information acquisition unit, a storage unit, a blood sugar determination unit, and an information organization unit. When the blood sugar determination unit determines that a measured blood sugar value is within a predetermined range, the information organization unit deletes meal information corresponding to the measured blood sugar value from the storage unit, and when the blood sugar determination unit determines that the measured blood sugar value is not within the predetermined range, the information organization unit holds meal information corresponding to the measured blood sugar value in the storage unit.

traducir

Systems and Methods for Risk Based Insulin Delivery Conversion

NºPublicación: US2022246264A1 04/08/2022

Solicitante:

DEXCOM INC [US]

US_2022256227_A1

Resumen de: US2022246264A1

Systems and methods are provided for managing hyperglycemia and hypoglycemia by reconciling incoming data to provide safe and reliable control to range using automatic bolus determination wherein the rate of insulin delivery is dependent on the level of hyperglycemic risk or hypoglycemic risk. Additionally, some implementations are directed to converting insulin delivery into a rate based on glycemic risk.

traducir

SYSTEMS AND METHODS FOR INCORPORATING CO-FORMULATIONS OF INSULIN IN AN AUTOMATIC INSULIN DELIVERY SYSTEM

NºPublicación: US2022241504A1 04/08/2022

Solicitante:

INSULET CORP [US]

US_2022240847_A1

Resumen de: US2022241504A1

Disclosed herein are systems and methods for the delivery of a co-formulation of insulin and a second drug, such as GLP-1, using an automated insulin delivery system. In a first embodiment, a dose of insulin is calculated by a medication delivery algorithm and a reduction factor is applied to account for the effect of second drug on the user's daily insulin requirement. In a second embodiment of the invention, a total amount of the second drug administered to the user during the past 24 hours is used to modify the correction factor and the insulin-to-carbohydrate ratio used by the medication delivery algorithm to cause a reduction in the insulin delivered to the user to account for the effect of the administration of the second drug portion of the co-formulation.

traducir

GLUCOSE LEVEL MANAGEMENT WITHOUT CARBOHYDRATE COUNTING

NºPublicación: US2022241500A1 04/08/2022

Solicitante:

MEDTRONIC MINIMED INC [US]

CN_114822757_PA

Resumen de: US2022241500A1

Disclosed herein are techniques related to glucose level management without carbohydrate counting. The techniques may involve obtaining contextual information for a meal, predicting amounts of glucose to be absorbed into a bloodstream of the patient over a duration of time due to consumption of the meal based on the contextual information for the meal, determining one or more amounts of insulin to counteract effects of the predicted amounts of glucose, and affecting insulin therapy based on outputting information indicative of the determined one or more amounts of insulin.

traducir

AUTOMATED INSULIN DELIVERY SYSTEM USING PRAMLINTIDE

Nº publicación: US2022240847A1 04/08/2022

Solicitante:

INSULET CORP [US]

US_2022241504_A1

Resumen de: US2022240847A1

Disclosed herein are systems and methods for the delivery of insulin and pramlintide using an automated insulin delivery system. In a first embodiment, a drug delivery system is configured to deliver independent doses of insulin and pramlintide. The system monitors the user's blood glucose level and determines when a meal is been ingested and, in response, delivers the dose of pramlintide which, in turn alters the required delivery of insulin. In the second embodiment, the drug delivery system is configured to deliver a co-formulation of insulin and pramlintide as basal doses. The total amount of pramlintide delivered in a most recent pre-determine period of time, for example, 24 hours, is used to alter the aggressiveness of the algorithm which determines the basal doses of the co-formulation.

traducir

Página1 de 4 nextPage por página

punteroimgVolver